Subscribe To
PHAT / Phathom Pharma's Digestive Disease Candidate Meets Primary Goal In Mid-Stage Study
PHAT News
By GlobeNewsWire
October 25, 2023
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing more_horizontal
By Seeking Alpha
October 5, 2023
Following Up On Phathom Pharmaceuticals
Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some more_horizontal
By Seeking Alpha
July 14, 2023
Phathom Pharma: Time To Take Profits (Rating Downgrade)
Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take p more_horizontal
By Zacks Investment Research
June 1, 2023
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after me more_horizontal
By Zacks Investment Research
May 26, 2023
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In more_horizontal
By Zacks Investment Research
March 27, 2023
Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In more_horizontal
By Zacks Investment Research
March 7, 2023
All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy
Phathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. T more_horizontal
By Market Watch
February 10, 2023
Phathom's stock falls after receiving FDA letters
Shares of Phathom Pharmaceuticals Inc. PHAT, -0.60% tumbled about 23% in premarket trading on Friday, the day after the company said it received compl more_horizontal